Lung Cancer

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.

Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone.

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S.

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

Targeted therapies have changed non-small cell lung cancer care, but new side effects, like weight gain, are emerging, says Dr. Lorenzo Belluomini.

Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.

After years of chronic cough and misdiagnosed infections, a 2016 stage 4 ALK-positive lung cancer diagnosis led to targeted therapy that has helped since.

LiveLung announced the launch of its new Chaplain Program.

It is very important to let the world know that no matter how healthy you think you are, if you have lungs, you can potentially develop lung cancer.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Nancee Pronsati discusses a new patient-authored guide for managing ALK-directed treatment side effects in lung cancer and improving quality of life.

The first day of fall comes on September 22, and every year it feels like a reminder to pause.

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.

Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.

Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; studies are currently enrolling.

Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.

For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.

Receiving a “Stand Up to Cancer Day” email gave me the strength to support a friend through her darkest cancer days.

When I think about standing up to cancer, I cannot separate the words from my own story.

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.

Perioperative immunotherapy for the treatment of non-small cell lung cancer is starting to exhibit survival benefits among patients, research has shown.

Over the past 20 years, there have been dramatic advances in treatment options for people diagnosed with non-small cell lung cancer

LiveLung invites the Pittsburgh community to its monthly educational meeting.